U.S. markets closed

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8826-0.0294 (-3.22%)
At close: 04:00PM EDT
0.8455 -0.04 (-4.20%)
After hours: 07:23PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close0.9120
Bid0.9345 x 2900
Ask0.9400 x 1300
Day's Range0.8086 - 0.9500
52 Week Range0.5820 - 4.6500
Avg. Volume617,622
Market Cap44.776M
Beta (5Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-1.4600
Earnings DateMay 16, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AGTC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Applied Genetic Technologies Co
    QURE: What does Argus have to say about QURE?UNIQURE NV has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    AGTC to Present at the H.C. Wainwright Global Investment Conference

    GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, Jon Lieber, Chief Financial Officer, and Susan Schneider, Chief Medic

  • Benzinga

    Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months

    Applied Genetic Technologies Corp (NASDAQ: AGTC) reported three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa (XLRP), an inherited condition causing progressive vision loss in boys and young men. AGTC-501 is a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene. There were robust improvements in visual sensitivity, the trial's primary efficacy endpoint, in multiple patients three months after dosing, with

  • GlobeNewswire

    AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

    – 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study’s Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Results from the Phase 1/2 Trial in XLRP – – Company to Host Conference Call to Review Data on May 17 at 8:00 a.m. ET – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stag